ArticleTherapeutic advances in musculoskeletal disease2025
Late-onset psoriatic arthritis: data from a nationwide cross-sectional study.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A proportion of patients with psoriatic arthritis (PsA) have their disease onset after the age of 60 (Late-onset PsA-LoPsA). Objectives: To examine whether this subgroup exhibits distinct characteristics, disease outcomes, and treatment patterns. Design: Cross-sectional, observational study. Methods: Data were collected cross-sectionally from 805 PsA patients in a real-life, multicenter, nationwide study. Among them, we identified 130 patients (16%) with LoPsA (disease onset ⩾60 years). Univariable analyses were conducted to compare the characteristics of LoPsA with the rest of the cohort and multivariable logistic regression was performed to identify factors independently associated with LoPsA. Results: After controlling for potential confounders, LoPsA patients were less likely to report a family history of psoriasis (OR: 0.18, 95% CI: 0.05-0.64). At diagnosis, the LoPsA group displayed more than 2-fold higher probability of presenting with polyarthritis (OR: 2.13, 95% CI: 1.11-4.09) while during their disease course, they had a 50% lower probability of developing enthesitis (OR: 0.50, 95% CI: 0.26-0.98). Patients with LoPsA exhibited a higher rate of comorbidities such as diabetes mellitus (OR: 3.17, 95% CI: 1.56-6.43) and hypertension (OR: 4.03, 95% CI: 2.02-8.04), and were more likely to develop major adverse cardiovascular events (MACEs), (OR: 4.83, 95% CI: 1.56-14.92). There were no differences in treatment patterns, disease outcomes, and damage indices between the two patient groups. Conclusion: Patients with LoPsA were more likely to present with polyarthritis, had lower odds of developing enthesitis, and were more frequently observed to have comorbidities and MACEs. Overall, their treatment patterns and disease outcomes did not differ from patients with early onset PsA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.